Nitric Oxide Synthase Inhibitors into the Clinic at Last

Abstract

published version features the final layout of the paper including the volume, issue and page numbers. Link to publication General rightsCopyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal.If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User

Endothelial reactive oxygen-forming NADPH oxidase 5 is a possible player in diabetic aortic aneurysm but not atherosclerosis

“…As an outlook, it would be of interest to examine the role of Nox5 in other models and types 25 of abdominal aortic aneurysm, e.g., ApoE −/− mice infused with angiotensin II 25,42 . Rather than the down-stream mechanistic consideration, it will be of interest to test Nox5 specific inhibitors for their therapeutic potential once they become available 43,44 .…”

Recent advances on endogenous gasotransmitters in inflammatory dermatological disorders

“…This evidence indicates a possible use of NO inhibitors and potential targets for improving NO bioavailability in the treatment of psoriasis. However, as reported by Dao VT et al ., all clinical attempts to inhibit NOS seem to have failed even though with positive results in preclinical models [91] . More scientific studies may be needed to explore the efficiency of these NOS inhibitors.…”

Targeting Nitric Oxide: Say NO to Metastasis

“…Another limitation that may explain why there is a scarcity of oncology clinical trials evaluating the efficacy of NOS inhibitors is that certain animal models may not be highly predictive of outcomes in human clinical trials ( 110 ). This is despite efforts to match preclinical/clinical characteristics and endpoints.…”

“…Differences in the inducibility and relevance of NOS2 in rodents and humans may also contribute to why preclinical studies do not completely recapitulate clinical trial outcomes ( 65, 111 ). In order to have a better understanding of clinically relevant and efficacious concentrations of NOS inhibitors to work with in the preclinical setting, it is worthwhile reevaluating the relevancy of preclinical laboratory models and utilizing more sophisticated in vitro human models with multiple cell types/matrices ( 110 ).…”